Evidence map›Paper›PMID 36151544›Full record

ArticleBMC endocrine disorders2022

Uygur type 2 diabetes patient fecal microbiota transplantation disrupts blood glucose and bile acid levels by changing the ability of the intestinal flora to metabolize bile acids in C57BL/6 mice.

Chanyue Wang, Ye Wang, Hao Yang, Zirun Tian, Manli Zhu, Xiaoting Sha, Ju Ran, Linlin Li

Open access · goldAbstract read
In one paragraph

Article in BMC endocrine disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  5. Review
  6. Advances in fecal microbiota transplantation for the treatment of diabetes mellitus.Frontiers in cellular and infection microbiology · 2024
    Review
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Chanyue WangPharmacological Department, Pharmacy College, Xinjiang Medical University, Urumqi, Xinjiang, China.
Ye WangPharmacological Department, Pharmacy College, Xinjiang Medical University, Urumqi, Xinjiang, China.
Hao YangPharmacological Department, Pharmacy College, Xinjiang Medical University, Urumqi, Xinjiang, China.
Zirun TianPharmacological Department, Pharmacy College, Xinjiang Medical University, Urumqi, Xinjiang, China.
Manli ZhuPharmacological Department, Pharmacy College, Xinjiang Medical University, Urumqi, Xinjiang, China.
Xiaoting ShaPharmacological Department, Pharmacy College, Xinjiang Medical University, Urumqi, Xinjiang, China.
Ju RanPharmacological Department, Pharmacy College, Xinjiang Medical University, Urumqi, Xinjiang, China.
Linlin LiPharmacological Department, Pharmacy College, Xinjiang Medical University, Urumqi, Xinjiang, China. 442338720@qq.com.
Xinjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOur epidemiological study showed that the intestinal flora of Uygur T2DM patients differed from that of normal glucose-tolerant people. However, whether the Uygur T2DM fecal microbiota transplantation could reproduce the glucose metabolism disorder and the mechanism behind has not been reported. This study was designed to explore whether Uygur T2DM fecal microbiota transplantation could reproduce the glucose metabolism disorder and its mechanism.

methodsThe normal diet and high fat diet group consisted of C57BL/6 mice orally administered 0.2 mL sterile normal saline. For the MT (microbiota transplantation) intervention groups, C57BL/6 mice received oral 0.2 mL faecal microorganisms from Uygur T2DM. All mice were treated daily for 8 weeks and Blood glucose levels of mice were detected. Mice faecal DNA samples were sequenced and quantified using 16S rDNA gene sequencing. Then we detected the ability of the intestinal flora to metabolize bile acids (BAs) through co-culture of fecal bacteria and BAs. BA levels in plasma were determined by UPLC-MS. Further BA receptors and glucagon-like peptide-1 (GLP-1) expression levels were determined with RT-q PCR and western blotting.

resultsMT impaired insulin and oral glucose tolerance. Deoxycholic acid increased and tauro-β-muricholic acid and the non-12-OH BA:12-OH BA ratio decreased in plasma. MT improved the ability of intestinal flora to produce deoxycholic acid. Besides, the vitamin D receptor in the liver and ileum and GLP-1 in the ileum decreased significantly.

conclusionsUygur T2DM fecal microbiota transplantation disrupts glucose metabolism by changing the ability of intestinal flora to metabolize BAs and the BAs/GLP-1 pathway.

Indexed as

Diabetes Mellitus, Type 2Gastrointestinal MicrobiomeAnimalsBile Acids and SaltsBlood GlucoseChromatography, LiquidDeoxycholic AcidDNA, RibosomalFecal Microbiota TransplantationGlucagon-Like Peptide 1HumansInsulinMiceMice, Inbred C57BLReceptors, CalcitriolSaline SolutionBile Acids and SaltsBlood GlucoseDeoxycholic AcidDNA, RibosomalGlucagon-Like Peptide 1InsulinReceptors, CalcitriolSaline SolutionBile acidsInsulin resistanceMicrobiota transplantationType 2 diabetes mellitus

Identifiers

PMID36151544
PMCPMC9503279
OpenAlexW4297009252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.